Alpha Tau Medical Ltd (DRTS)
NASDAQ:DRTS
Top Page
Alpha Tau Medical Ltd
(NASDAQ:DRTS)
Select Model
Select Model
Rating:49Neutral
Price Target:
$7.00
▲(2.34% Upside)
Action:ReiteratedDate:03/12/26
The score is primarily held down by very weak financial performance (no revenue, widening losses, and significant ongoing cash burn), partially offset by a comparatively improved balance sheet and moderate leverage. Technicals are neutral-to-slightly constructive on longer-term moving averages, while valuation remains challenged due to negative earnings and no dividend support.
Positive Factors
Regulatory validation (Japan approval)
Securing Shonin approval in Japan provides durable regulatory validation for Alpha DaRT as a first-in-kind intratumoral alpha therapy. This creates an initial commercial foothold, obliges post-market study data generation, and materially reduces regulatory execution risk regionally versus a company with no approvals.
Negative Factors
No commercial revenue
Absent any product revenue, the business remains entirely pre-commercial; sustainable margins and profitability cannot be assessed until market uptake. This structural revenue void forces reliance on external financing and makes long-term viability contingent on successful trial outcomes and regulatory approvals.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory validation (Japan approval)
Securing Shonin approval in Japan provides durable regulatory validation for Alpha DaRT as a first-in-kind intratumoral alpha therapy. This creates an initial commercial foothold, obliges post-market study data generation, and materially reduces regulatory execution risk regionally versus a company with no approvals.
Read all positive factors
Alpha Tau Medical Ltd (DRTS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$646.87M
Dividend YieldN/A
Average Volume (3M)256.05K
Price to Earnings (P/E)―
Beta (1Y)0.85
Revenue GrowthN/A
EPS Growth-22.82%
CountryUS
Employees125
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.14
Shares Outstanding88,009,735
10 Day Avg. Volume185,030
30 Day Avg. Volume256,051
Financial Highlights & Ratios
PEG Ratio-0.53
Price to Book (P/B)5.17
Price to Sales (P/S)0.00
P/FCF Ratio-12.18
Enterprise Value/Market Cap1.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-15.52
Forecast
1Y Price Target
$8.67Price Target Upside26.75% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.5
Revenue Forecast (FY)$1.27M
Alpha Tau Medical Ltd Business Overview & Revenue Model
Company Description
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United S...
How the Company Makes Money
null...
Alpha Tau Medical Ltd Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
64
Positive
Cash Flow
23
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -1.23M | -1.10M | -1.07M | -979.00K | -776.00K |
| EBITDA | -41.06M | -30.30M | -28.03M | -32.74M | -13.21M |
| Net Income | -42.63M | -31.75M | -29.16M | -33.76M | -27.27M |
Balance Sheet | |||||
| Total Assets | 106.58M | 86.20M | 107.39M | 120.15M | 42.22M |
| Cash, Cash Equivalents and Short-Term Investments | 76.90M | 59.60M | 81.79M | 104.53M | 31.32M |
| Total Debt | 13.73M | 12.54M | 13.28M | 5.19M | 53.96M |
| Total Liabilities | 29.48M | 23.54M | 22.91M | 14.49M | 76.99M |
| Stockholders Equity | 77.10M | 62.67M | 84.47M | 105.66M | -34.78M |
Cash Flow | |||||
| Free Cash Flow | -32.76M | -22.02M | -24.36M | -24.78M | -14.74M |
| Operating Cash Flow | -26.68M | -19.78M | -17.96M | -23.88M | -11.81M |
| Investing Cash Flow | -20.59M | 20.77M | 18.68M | -89.94M | 19.27M |
| Financing Cash Flow | 45.77M | 25.00K | 5.30M | 96.91M | 111.00K |
Alpha Tau Medical Ltd Technical Analysis
Positive
6.84
Price Trends
7.20
Positive
6.17
Positive
4.88
Positive
Market Momentum
>-0.01
Negative
55.69
Neutral
75.16
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DRTS, the sentiment is Positive. The current price of 6.84 is below the 20-day moving average (MA) of 7.08, below the 50-day MA of 7.20, and above the 200-day MA of 4.88, indicating a bullish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 55.69 is Neutral, neither overbought nor oversold. The STOCH value of 75.16 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DRTS.
Alpha Tau Medical Ltd Risk Analysis
Alpha Tau Medical Ltd disclosed 81 risk factors in its most recent earnings report. Alpha Tau Medical Ltd reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Alpha Tau Medical Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $1.82B | -12.77 | -67.52% | ― | -52.08% | -69.35% | |
52 Neutral | $528.76M | -1.68 | -137.70% | ― | ― | -67.41% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $646.87M | -9.36 | -57.29% | ― | ― | -22.82% | |
49 Neutral | $378.24M | ― | -38.92% | ― | ― | 80.95% | |
49 Neutral | $476.38M | -63.66 | -67.33% | ― | ― | 4.97% | |
48 Neutral | $434.94M | -3.10 | -71.25% | ― | ― | -11.41% |
* Healthcare Sector Average
DRTS
Alpha Tau Medical Ltd
7.35
4.80
188.24%
LRMR
Larimar Therapeutics
5.09
3.28
181.22%
CAPR
Capricor Therapeutics
31.61
22.32
240.26%
BNTC
Benitec Biopharma
11.01
-1.62
-12.83%
AURA
Aura Biosciences Inc
6.78
1.48
27.92%
LXEO
Lexeo Therapeutics, Inc.
6.43
4.45
224.75%
Alpha Tau Medical Ltd Corporate Events
Alpha Tau Posts Wider 2025 Loss as Japanese Approval and U.S. Trial Progress Mark Pivotal Year
Mar 9, 2026
Alpha Tau Medical Ltd., the developer of the Alpha DaRT alpha-radiation cancer therapy, reported its full-year 2025 results on March 9, 2026, alongside a broad clinical and regulatory update. The company is expanding into major cancer indications ...
Alpha Tau Wins First Overseas Approval as Japan Clears Alpha DaRT Cancer Therapy
Feb 24, 2026
On February 24, 2026, Alpha Tau Medical Ltd. announced that Japan’s Ministry of Health, Labour and Welfare granted Shonin marketing approval for its Alpha DaRT therapy to treat unresectable locally advanced or locally recurrent head and neck...
Alpha Tau Outlines Aggressive 2026 Clinical Schedule and Manufacturing Ramp for Alpha DaRT Cancer Therapy
Jan 29, 2026
On January 29, 2026, Alpha Tau Medical issued a shareholder letter outlining an intensifying clinical and pre-commercial agenda for 2026, highlighted by five concurrent U.S. trials of its Alpha DaRT therapy in skin, pancreatic, brain and prostate ...
Alpha Tau Medical Unveils Strong Pancreatic Cancer Alpha DaRT Data Ahead of ASCO GI 2026
Jan 6, 2026
On January 6, 2026, Alpha Tau Medical reported final results from its first-in-human pancreatic ductal adenocarcinoma study in Montreal, showing an 81% disease control rate across 32 patients treated with its Alpha DaRT therapy, rising to 87% when...
Alpha Tau Files First FDA PMA Module for Alpha DaRT Skin Cancer Therapy
Jan 5, 2026
On January 5, 2026, Alpha Tau Medical announced it has submitted the first module of its pre-market approval application to the U.S. Food and Drug Administration for Alpha DaRT in the treatment of recurrent cutaneous squamous cell carcinoma in pat...
Alpha Tau Medical to Present Corporate Update at J.P. Morgan 2026 Healthcare Conference
Dec 18, 2025
On December 18, 2025, Alpha Tau Medical Ltd. announced that CEO Uzi Sofer and CFO Raphi Levy will deliver a corporate overview and update at the J.P. Morgan 2026 Healthcare Conference in San Francisco on January 15, 2026, and will hold one-on-one ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.